The 12 closest competitors and alternatives to Superluminal Medicines, Inc. among biotechnology companies — ranked by similarity to what Superluminal Medicines, Inc. actually does, not by market-cap band.
Subscribe to see Superluminal Medicines, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Superluminal Medicines, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $65.5M in August 2026. Xcout tracks 18 named people at Superluminal Medicines, Inc., including Cony D'Cruz (CEO). Xcout recorded 15 job postings from Superluminal Medicines, Inc. in the last 90 days.
12 more named people on record for Superluminal Medicines, Inc., with roles, board committees and tenure — see the full roster →
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $65.5M | 10 named | |
| SEC Form D filing | $5M | — | |
| Series A | $120M | 16 named | |
| Seed | $33M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Xcout recorded 15 job postings from Superluminal Medicines, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Superluminal Medicines, Inc.'s hiring signals →
Ranked by semantic similarity — how close each company is to Superluminal Medicines, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Similar biotechnology company
Standard Model Biomedicine is a biotechnology research company based in San Francisco, United States. The company is focused on developing a foundation model for human biology to advance biomedical research.
Biotech
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Similar biotechnology company
Avicenna Biosciences, Inc. is a biotechnology company that uses machine learning-enhanced medicinal chemistry to accelerate drug discovery and optimization.
Similar biotechnology company
Reverie Labs is a Cambridge, Massachusetts-based biotechnology company founded in 2017 that applied machine learning to drug discovery and developed brain-penetrant cancer therapies. In its operations, the company focused on accelerating preclinical drug development through lead generation and optimization using machine learning models and software.
Similar biotechnology company
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Biotech
Atomic AI is a biotechnology research company specializing in RNA drug discovery utilizing atomic precision. Headquartered in San Francisco, California, the company combines machine learning and biology to develop advanced therapeutics.
Biotech
PostEra Inc. is a U.S.-based biotechnology company that develops machine-learning and computational chemistry software for drug discovery and medicinal chemistry. Its platform helps pharmaceutical and biotechnology organizations design, prioritize, and manage experiments for small-molecule therapeutics.
Biotech
Harmonic Discovery is a drug discovery company founded in 2021 and headquartered in New York City. The company leverages machine learning and precision pharmacology to develop therapeutics for complex diseases.
Similar biotechnology company
Noetik Inc. is an AI-native biotechnology company headquartered in South San Francisco, California, leveraging advanced machine learning methods for biological discovery.
Similar biotechnology company
Engine Biosciences is a Singapore-based biotechnology company and venture-creation platform that combines machine learning, computational biology, and laboratory experimentation to discover and develop new medicines. It builds and invests in therapeutic-focused biotech companies, serving pharmaceutical and healthcare markets.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Superluminal Medicines, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →